CODX - CIK 0001692415
The table below shows Co-Diagnostics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$29.14M | -$29.16M | -$22.08M | $6.57M | $41.08M | $28.17M |
| Capital expenditure | $700.05K | $748.35K | $1.37M | $1.43M | $669.46K | $774.40K |
| Investing cash flow | $26.27M | $17.07M | $15.39M | -$58.17M | $4.10M | -$5.82M |
| Dividends paid | - | - | - | - | - | - |
Co-Diagnostics, Inc. reported operating cash flow of -$29.14M for fiscal year 2025. That is up 0.1% from -$29.16M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$1.31M (FY 2016) to -$29.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | $1.36M | $14.21M | - | - |
| Financing cash flow | $11.81M | $103.91K | -$1.36M | -$14.03M | $450.40K | $19.74M |